The global vaginal pessaries market is witnessing steady expansion as awareness of women’s pelvic health and non-surgical treatment options continues to rise. Valued at US$ 473.4 million in 2024, the market is projected to grow at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2035, ultimately reaching US$ 864.4 million by 2035. This growth is supported by increasing acceptance of vaginal pessaries as a first-line management solution for pelvic organ prolapse (POP) and urinary incontinence, conditions that affect millions of women worldwide.
Analysts’ Viewpoint
Analysts highlight that the vaginal pessaries market’s growth trajectory is being shaped by heightened public awareness, technological innovation, and strategic collaborations across the healthcare ecosystem. Medical device manufacturers are focusing on user-friendly, biocompatible, and customizable pessary designs, such as 3D-printed and flexible silicone pessaries, to improve patient comfort and clinical outcomes. Hospitals and universities are increasingly partnering with device manufacturers to generate strong clinical evidence that enhances safety and boosts clinician confidence in recommending pessaries.
Furthermore, favorable reimbursement policies in developed economies and the rise of telehealth consultations for pelvic floor disorders have expanded accessibility to pessary-based treatments. These dynamics are making pessaries a preferred choice among both healthcare providers and patients seeking minimally invasive management options.
Market Introduction and Current Trends
The vaginal pessaries market has entered a phase of strategic segmentation and rapid innovation. Shipment volumes have consistently risen at over 5.7% CAGR, particularly across gynecology care centers and outpatient clinics. Recent data suggests a significant transition toward single-use disposable pessaries, which now account for nearly 60% of new product entries, up from less than 30% in 2020.
Meanwhile, reusable pessaries have gained traction in developing regions, growing from under 10% to over 20% in usage within two years due to affordability and sustainability advantages. Importantly, the proportion of women aged 50–70 using pessaries has surpassed 50% in key markets—a significant increase from just 35% a year earlier.
Additionally, telehealth-based gynecological consultations for POP management now represent roughly 25% of virtual gynecology visits, reflecting a major shift in how patients are engaging with pelvic health professionals.
Rising Prevalence of Pelvic Floor Disorders Drives Market Growth
One of the primary market drivers is the rising global prevalence of pelvic organ prolapse (POP) and urinary incontinence. The International Urogynecology Association (IUGA) reports that nearly 50% of women over 50 experience some form of POP. With global life expectancy rising, the number of women at risk of pelvic floor dysfunction continues to grow, thereby sustaining long-term demand for pessary devices.
Surgical options for these conditions often involve prolonged recovery times and potential complications, prompting healthcare providers to recommend vaginal pessaries as a first-line, non-invasive treatment. For example, in Australia, the Royal Women’s Hospital observed a 35% increase in pessary fittings between 2019 and 2022, reflecting a major shift toward conservative POP management. Similar adoption trends have been reported in Germany, Japan, and the U.S., where hospitals are emphasizing patient-centered, non-surgical interventions for elderly women.
Growing Acceptance of Non-Surgical Solutions
Increasing awareness campaigns and updated clinical guidelines have transformed patient attitudes toward pessary use. Once viewed as outdated, pessaries are now recognized as effective, comfortable, and discreet alternatives for managing pelvic floor disorders.
In 2022, the American College of Obstetricians and Gynecologists (ACOG) reaffirmed its recommendation of pessaries as a first-line therapy for Stage I and II POP, catalyzing higher prescription rates among gynecologists and physiotherapists. This endorsement has significantly boosted confidence among both clinicians and patients.
Educational outreach in developing nations has also contributed to rising adoption. For instance, India’s Ministry of Health, in collaboration with FOGSI, launched a 2023 campaign distributing educational materials on pessary use to rural communities. Similarly, Amref Health Africa in Kenya facilitated over 2,000 pessary fittings in a single year, proving the feasibility of pessary interventions even in low-resource settings.
Dominance of Ring Pessary Segment
Among various product types, the ring pessary segment remains the market leader, accounting for approximately 45–50% of total global sales volume. Their dominance is attributed to ease of use, versatility, and high patient comfort, especially in managing mild to moderate POP cases.
In 2024, ring pessaries captured nearly 48% of unit sales across Europe and North America, outperforming other models such as cube, Gehrung, and Gellhorn types. Hospitals in Germany reported a 35% rise in ring pessary fittings during a six-month trial, primarily due to advancements in flexible silicone designs.
Moreover, the introduction of integrated retention wings has reduced adverse events by around 15%, enhancing patient safety. Manufacturers now actively market ring pessaries as adaptive and easy-to-fit solutions, reinforcing their position as the cornerstone of the vaginal pessaries industry.
Regional Insights: North America Leads the Market
North America continues to dominate the vaginal pessaries market, supported by strong healthcare infrastructure, well-established reimbursement frameworks, and advanced patient education systems. Increased awareness of pelvic health and non-surgical options among women has encouraged widespread adoption across the U.S. and Canada.
Hospitals and outpatient clinics in the region report a 40% increase in pessary-related consultations over the past two years, reflecting growing clinical acceptance. Furthermore, Medicare and private insurers have expanded coverage for pessary fittings, reducing out-of-pocket expenses and encouraging more women to seek treatment.
The presence of key medical device manufacturers and ongoing clinical trials in the U.S. also underpin regional leadership. For instance, a 2024 study involving 500 U.S. participants revealed a 90% satisfaction rate with a proprietary silicone ring pessary, prompting some insurers to enhance coverage for pessary-based treatments.
In addition, major medical societies and academic centers continue to publish guidelines and best practices, ensuring consistent training and safe usage—factors that collectively fortify North America’s leadership position through 2035.
Competitive Landscape and Future Outlook
Leading companies in the vaginal pessaries market are investing heavily in product innovation, partnerships, and material science advancements. Prominent players include Narang Medical Limited, Bray Group, Mediplus Ltd., Integra LifeSciences, Cooper Surgical, MedGyn, Dr. Arabin GmbH & Co. KG, and Bioteque America.
In May 2025, one manufacturer announced the expansion of its POPY pessary product line, adding five new sizes to improve comfort and fit precision for women with POP. This exemplifies the ongoing industry commitment to personalized pelvic care and patient-centric device design.
Going forward, market expansion will be driven by clinical validation studies, digital health integration, and broader patient outreach initiatives that destigmatize pelvic health issues. With rising life expectancy and continued innovation, the vaginal pessaries market is poised for sustainable growth, achieving a global valuation of US$ 864.4 million by 2035.
In summary, the next decade will see vaginal pessaries evolve from niche therapeutic aids into mainstream, evidence-based solutions that empower women worldwide to manage pelvic health effectively and non-surgically.
